Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 126

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 126
---
 or competition laws.                                                                                                                                                                 |

| (d) | The Company, its Subsidiary and, to the knowledge of the Company, their respective directors, officers,                                                                                                                                   
 employees, agents and other persons acting on behalf of the Company or its Subsidiary, are and have at all times been in material compliance with all applicable anti-money laundering laws, rules, and regulations, including anti-money 
 laundering-related government guidance (collectively, “AML Laws”). There is no pending investigation, inquiry or enforcement action against the Company, its Subsidiary or, to the knowledge of the Company, any of their respective      
 officers, directors or employees relating to any violation or potential violation of any AML Law related to the Company’s business.                                                                                                       |

| 35. | Sanctions |

| (a) | Neither the Company nor its Subsidiary nor, to the knowledge of the Company, their respective directors,                                                                                                                                                  
 officers, employees, agents or other persons acting on behalf of the Company or its Subsidiary are, or are directly or indirectly owned, held or controlled by or on behalf of, any person or persons listed on any list of designated persons subject to 
 international sanctions or trade embargoes imposed, authorized, administered or enforced by any Governmental Entity of Canada, the United States, the UK, or the EU or its member states (collectively, “Sanctions”).                                     |

| (b) | Neither the Company nor its Subsidiary are organized, resident or located in any country or territory that is                                                                                                                                   
 the target of comprehensive Sanctions, including (as at the date hereof) Belarus, Central African Republic, China, Democratic People’s Republic of Korea (North Kora), Democratic Republic Of the Congo, Guatemala, Haiti, Iran, Iraq, Lebanon, 
 Libya, Moldova, Myanmar, Nicaragua, Russia, Somalia, South Sudan, Sri Lanka, Sudan, Syria, the occupied Crimea, Donetsk, Luhansk, Kherson and Zaporizhzhia regions of Ukraine, Venezuela, Yemen and Zimbabwe.                                   |

E-14

| 36. | Consents and Approvals |

| (a) | Other than as set out in Schedule 36 to the Disclosure Letter, there are no Regulatory Approvals required to be 
 obtained by the Company in order to complete the Contemplated Transactions and the Distribution.                |

| (b) | There is no requirement under applicable Securities Laws for the Company to make any filing, give